Published by Harvest ETFs

Johnson & Johnson was named to Fortune’s list of the World’s Most Admired companies recently, for the 17th year in a row.

J&J made the list because of its innovative spirit and commitment to social responsibility, among other respected attributes. It also placed #1 in the Pharmaceutical category worldwide for the 6th consecutive year, making it the highest-ranked healthcare company to appear on the top companies list in 2019.

Johnson & Johnson is a U.S. multinational founded in 1886 that makes medical devices, pharmaceutical and consumer packaged goods. It employs 125,000 people.

Johnson & Johnson is an example of an enduring global brand. Its consumer products include such well-known names as Johnson & Johnson baby care products, Band-Aid bandages and over the counter drugs including Tylenol, Benadryl and Motrin. Its medical devices and supplies include sutures and laparoscopic surgical devices. The pharmaceutical division develops treatments for immune deficiency and cardiovascular and metabolic diseases, as well as family planning products.

Fortune asked hundreds of executives to rate organizations in dozens of industries on such criteria as quality of management, innovativeness, social responsibility and an ability to attract and retain talented people.

Also, in the top 20 were Apple -the world’s most admired brand, Walt Disney Co., J.P. Morgan and Microsoft. These companies are among the top holdings in the Harvest Portfolio Group Harvest Brand Leaders Plus Income ETF (TSX: HBF)

The fund invests in 20 global brand leaders that have a minimum market capitalization of US$10 billion at the time of investment. As of Feb. 28, 2019, the ETF had an average dividend yield of 2.04% and an average P/E ratio of 17.9. It is eligible for RRSPs and TFSAs. The dividends are available as cash or DRIPs.

For more on Harvest Portfolio Group ETF products click here.

The views and/or opinions expressed in the blog are of a general nature and are for informational purposes only. Blog contents should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Investors should consult their investment advisor before making any investment decision.